IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 13 2022 - 7:30AM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company discovering and developing innovative gamma-delta T cell
therapies that utilize its DeltEx platform, today announced William
Ho, IN8bio’s Chief Executive Officer will be participating in a
fireside chat at 10:30 a.m. ET tomorrow, Wednesday, September 14,
at the H.C. Wainwright & Co. 24th Annual Global Investment
Conference.
The fireside chat will be available live on the IN8bio website
or at this link. A replay will be available for approximately 90
days following the conference.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on discovering, developing and
commercializing gamma-delta T cell product candidates for solid and
liquid tumors. Gamma-delta T cells are a specialized population of
T cells that possess unique properties, including the ability to
differentiate between healthy and diseased tissue. IN8bio’s DeltEx
platform employs allogeneic, autologous, iPSC, and genetically
modified approaches to develop cell therapies that synergize with
chemotherapy to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
leukemia undergoing hematopoietic stem cell transplantation. IN8bio
also has a broad portfolio of preclinical programs focused on
addressing other solid tumor types. For more information about
IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From May 2024 to Jun 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Jun 2023 to Jun 2024